Key Events This Week
23 Feb: Stock hits 52-week low of Rs.352.6 amid financial concerns
24 Feb: Further decline to Rs.350.45 with valuation metrics signalling renewed price attractiveness
26 Feb: New 52-week low of Rs.345.2 as debt and earnings pressure persist
27 Feb: Week closes at Rs.347.20, marking a 5.90% weekly fall
23 February 2026: Stock Hits 52-Week Low of Rs.352.6
Unichem Laboratories Ltd’s share price plunged to a new 52-week low of Rs.352.6 on 23 February, marking a sharp 3.33% decline on the day. This drop occurred despite the Sensex gaining 0.39%, underscoring the stock’s underperformance relative to the broader market. The stock’s fall was driven by mounting concerns over the company’s financial health, including a high Debt to EBITDA ratio of 4.87 times and weak profitability metrics such as an average Return on Equity (ROE) of 1.44%.
Quarterly results released recently revealed a 77.2% contraction in Profit Before Tax excluding other income to Rs.6.11 crores and a 56.0% decline in Profit After Tax to Rs.16.13 crores, further dampening investor sentiment. Interest expenses surged by 30.50% to Rs.15.66 crores over six months, adding to financial strain. The stock’s technical position remained weak, trading below all key moving averages, signalling sustained downward momentum.
24 February 2026: Fresh 52-Week Low and Valuation Reassessment
The downward trend continued on 24 February as the stock fell further to Rs.350.45, marking another 52-week low and a 0.43% decline from the previous day’s close. The Sensex, meanwhile, declined 0.78%, reflecting broader market pressures. Despite the price weakness, valuation metrics showed signs of renewed attractiveness. The company’s price-to-earnings (P/E) ratio stood at 23.89, with a price-to-book value of 1.03, positioning Unichem as very attractively valued relative to its sector peers.
Unichem’s enterprise value to EBITDA ratio of 12.97 was notably lower than competitors such as Ajanta Pharma and J B Chemicals, suggesting potential value for investors seeking exposure to the pharmaceutical sector at a discount. The company’s Price/Earnings to Growth (PEG) ratio of 0.8 further indicated undervaluation relative to earnings growth. However, the stock’s Mojo Score remained low at 31.0 with a Sell rating, reflecting ongoing caution.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
25 February 2026: Minor Recovery Amid Low Volumes
On 25 February, Unichem Laboratories saw a slight rebound, closing at Rs.357.00, up 0.54% on very low volume. This modest gain contrasted with the Sensex’s 0.41% rise, indicating limited buying interest. The stock’s technical indicators remained weak, and the underlying financial challenges persisted. The slight uptick did little to alter the prevailing negative sentiment driven by high leverage and subdued profitability.
26 February 2026: New 52-Week Low of Rs.345.2 Amid Continued Pressure
The stock resumed its decline on 26 February, hitting a fresh 52-week low of Rs.345.2 and closing down 1.15%. This drop occurred despite the Sensex gaining 0.19%, highlighting Unichem’s ongoing underperformance. The company’s financial metrics remained a concern, with a Debt to EBITDA ratio of 4.87 times and a low ROE of 1.44%. Quarterly earnings continued to disappoint, with Profit Before Tax excluding other income down 77.2% and Profit After Tax down 56.0% compared to prior averages.
Interest expenses increased by 30.50%, further pressuring earnings and cash flow. Despite robust long-term operating profit growth at an annualised 148.09%, these gains have yet to translate into improved shareholder returns. The stock’s valuation remained attractive, with a Return on Capital Employed (ROCE) of 4.9% and an enterprise value to capital employed ratio of 1, but market sentiment stayed cautious.
Is Unichem Laboratories Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
27 February 2026: Week Closes at Rs.347.20 on Continued Weakness
Unichem Laboratories ended the week at Rs.347.20, down 1.62% on 27 February and marking the lowest close in 52 weeks. The stock’s decline came amid a broadly negative market, with the Sensex falling 1.16%. The stock underperformed its Pharmaceuticals & Biotechnology sector by 0.92%, reflecting persistent investor concerns about the company’s financial health.
Technical indicators remained bearish, with the stock trading below all major moving averages. The company’s elevated Debt to EBITDA ratio of 4.87 times and modest ROE of 1.44% continue to weigh on sentiment. Despite a 29.9% rise in profits over the past year and a PEG ratio of 0.8 signalling valuation appeal, the market remains cautious due to earnings volatility and high interest expenses.
Daily Price Comparison: Unichem Laboratories Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-23 | Rs.356.65 | -3.33% | 36,817.86 | +0.39% |
| 2026-02-24 | Rs.355.10 | -0.43% | 36,530.09 | -0.78% |
| 2026-02-25 | Rs.357.00 | +0.54% | 36,679.75 | +0.41% |
| 2026-02-26 | Rs.352.90 | -1.15% | 36,748.49 | +0.19% |
| 2026-02-27 | Rs.347.20 | -1.62% | 36,322.56 | -1.16% |
Key Takeaways
Unichem Laboratories Ltd’s stock performance this week was marked by persistent declines, hitting multiple 52-week lows and closing the week down 5.90%. The stock consistently underperformed the Sensex, which fell by 0.96% over the same period. Key factors driving this underperformance include the company’s high leverage, with a Debt to EBITDA ratio of 4.87 times, and subdued profitability metrics such as a low ROE of 1.44% and a modest ROCE of 4.9%.
Recent quarterly results revealed sharp contractions in profit before tax and after tax, alongside rising interest expenses, which have added pressure on earnings and cash flow. Despite these challenges, the company’s valuation metrics have improved, with a P/E ratio of 23.89 and a PEG ratio of 0.8, indicating potential undervaluation relative to earnings growth. Operating profit growth over five years remains robust at an annualised 148.09%, and net sales have grown steadily at 11.95% CAGR.
However, the market’s cautious stance is reflected in the Mojo Score of 31.0 and a Sell rating, signalling that while valuation is attractive, fundamental risks remain significant. The stock’s technical position remains weak, trading below all major moving averages, which may continue to weigh on near-term price action.
Conclusion
The week’s developments for Unichem Laboratories Ltd underscore a challenging environment characterised by financial pressures and subdued profitability, which have driven the stock to fresh 52-week lows. While valuation metrics suggest the stock is attractively priced relative to its earnings growth potential, persistent concerns over debt servicing capacity and earnings volatility continue to weigh on investor sentiment.
Unichem’s long-term operating profit growth and steady sales expansion offer some positive context, but these have yet to translate into improved returns for shareholders. The stock’s underperformance relative to the Sensex and sector peers highlights the need for cautious monitoring of operational and financial improvements before a more positive outlook can be established.
Investors should remain attentive to upcoming quarterly results and any shifts in the company’s leverage and profitability metrics, which will be critical in determining the stock’s trajectory amid a complex Pharmaceuticals & Biotechnology sector landscape.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
